These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Mouse models of dominant optic atrophy: what do they tell us about the pathophysiology of visual loss? Williams PA; Morgan JE; Votruba M Vision Res; 2011 Jan; 51(2):229-34. PubMed ID: 20801145 [TBL] [Abstract][Full Text] [Related]
7. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Zanna C; Ghelli A; Porcelli AM; Karbowski M; Youle RJ; Schimpf S; Wissinger B; Pinti M; Cossarizza A; Vidoni S; Valentino ML; Rugolo M; Carelli V Brain; 2008 Feb; 131(Pt 2):352-67. PubMed ID: 18222991 [TBL] [Abstract][Full Text] [Related]
15. The molecular mechanisms of OPA1-mediated optic atrophy in Drosophila model and prospects for antioxidant treatment. Yarosh W; Monserrate J; Tong JJ; Tse S; Le PK; Nguyen K; Brachmann CB; Wallace DC; Huang T PLoS Genet; 2008 Jan; 4(1):e6. PubMed ID: 18193945 [TBL] [Abstract][Full Text] [Related]
16. Increased steroidogenesis promotes early-onset and severe vision loss in females with OPA1 dominant optic atrophy. Sarzi E; Seveno M; Angebault C; Milea D; Rönnbäck C; Quilès M; Adrian M; Grenier J; Caignard A; Lacroux A; Lavergne C; Reynier P; Larsen M; Hamel CP; Delettre C; Lenaers G; Müller A Hum Mol Genet; 2016 Jun; 25(12):2539-2551. PubMed ID: 27260406 [TBL] [Abstract][Full Text] [Related]
17. OPA1: How much do we know to approach therapy? Del Dotto V; Fogazza M; Lenaers G; Rugolo M; Carelli V; Zanna C Pharmacol Res; 2018 May; 131():199-210. PubMed ID: 29454676 [TBL] [Abstract][Full Text] [Related]
18. Creation of an Isogenic Human iPSC-Based RGC Model of Dominant Optic Atrophy Harboring the Pathogenic Variant c.1861C>T (p.Gln621Ter) in the García-López M; Jiménez-Vicente L; González-Jabardo R; Dorado H; Gómez-Manjón I; Martín MÁ; Ayuso C; Arenas J; Gallardo ME Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000346 [TBL] [Abstract][Full Text] [Related]
19. Distributed abnormalities of brain white matter architecture in patients with dominant optic atrophy and OPA1 mutations. Rocca MA; Bianchi-Marzoli S; Messina R; Cascavilla ML; Zeviani M; Lamperti C; Milesi J; Carta A; Cammarata G; Leocani L; Lamantea E; Bandello F; Comi G; Falini A; Filippi M J Neurol; 2015 May; 262(5):1216-27. PubMed ID: 25794858 [TBL] [Abstract][Full Text] [Related]
20. Analysis of opa1 isoforms expression and apoptosis regulation in autosomal dominant optic atrophy (ADOA) patients with mutations in the opa1 gene. Formichi P; Radi E; Giorgi E; Gallus GN; Brunetti J; Battisti C; Rufa A; Dotti MT; Franceschini R; Bracci L; Federico A J Neurol Sci; 2015 Apr; 351(1-2):99-108. PubMed ID: 25796301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]